OriGene Developing Antibodies for SISCAPA Assays with NCI Contract | GenomeWeb

NEW YORK (GenomeWeb News) – OriGene Technologies announced that it has received a contract from the National Cancer Institute to develop high affinity anti-peptide antibodies for SISCAPA assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.